3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Lymphoma
3
Stomatitis
2
Small Cell Lung Carcinoma
2
Neoplasms
2
Mucositis
2
Mouth Neoplasms
2
Lung Neoplasms
2
Head and Neck Neoplasms
2
Carcinoma, Small Cell
2
Brain Neoplasms
2
Spinal Cord Neoplasms
1
Neuroendocrine Tumors
1
Neoplasm Metastasis
1
Colorectal Neoplasms
1
Cholangiocarcinoma
1
Central Nervous System Neoplasms
1
Carcinoma, Squamous Cell
1
Carcinoma, Ovarian Epithelial
1
Carcinoma, Non-Small-Cell Lung
1
Interventions
Gemcitabine
112
Cisplatin
76
Oxaliplatin
44
pembrolizumab
34
Fluorouracil
32
Capecitabine
30
durvalumab
27
Leucovorin
26
lenvatinib
23
Magnetic Resonance Spectroscopy
15
Irinotecan
14
Nivolumab
12
Biopsy
12
Albumin-Bound Paclitaxel
12
tislelizumab
11
Specimen Handling
11
Radiofrequency Ablation
11
Drug Therapy
11
pemigatinib
10
apatinib
10
Taxes
10
Floxuridine
10
130-nm albumin-bound paclitaxel
10
Radiotherapy
9
Bevacizumab
9
Platinum
8
Folfox protocol
8
Carboplatin
8
1,2-diaminocyclohexaneplatinum II citrate
8
tremelimumab
7
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Interventional
×
Cholangiocarcinoma
×
RRx-001
×
Clear all
NCT02452970
2024-04-24
EPIC
EpicentRx, Inc.
Phase 2
Terminated
4 enrolled
6 charts